Taxotere and Baldness: What the Science Says
There is solid scientific evidence that shows an association between the chemotherapy drug Taxotere and permanent baldness. Thousands of women across the country are suing the maker of the drug, claiming that if they had known about this particular side effect they would have chosen another treatment option. Here is some information on what clinical studies show regarding Taxotere and this devastating condition.
As recently as 2006, the prevailing scientific belief was that Persistent Significant Alopecia (PSA) was relatively rare. PSA is defined as a loss of more than half of pre-chemotherapy hair thickness lasting for longer than six months. Most researchers believed that it was only a problem for people receiving high doses of strong chemotherapy.
That belief was challenged when this study on Taxotere was released. The author of the study, Dr. Scot Sedlacek, researched 500 patients whom he had treated from 1994 to 2004. He performed his study because he had noticed a significant amount of patients suffering from PSA after relatively routine chemotherapy sessions. He found that more than 6 percent of patients who had received Taxotere had developed PSA. Two of his patients still had PSA seven years after stopping Taxotere treatment.
This number is large enough to be considered a common side effect, yet the maker of the drug, Sanofi-Aventis, failed to warn doctors or patients. As a result, women who suffered PSA after taking Taxotere are taking legal action.
Baron & Budd may be able to help if you or someone you know developed PSA after taking Taxotere. Please contact us online or give us a call at 866-520-2755 for more information. We’ll listen to the details of your case and let you know what type of assistance we may be able to provide.